Circio

Oslo, Norway

Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.

$31.5M raised

Jun 2026

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Circio raised?

Circio has raised $31.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.

Who are Circio's investors?

Circio's investors include Innovation Norway, Birk Venture, Radium Hospital Research Foundation, Atlas Special Opportunities, Algot Invest.

Where is Circio headquartered?

Circio is headquartered in Oslo, Norway.

What does Circio do?

Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.

What stage is Circio at?

Circio is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 10, 2026.

MLA

"Circio — Funding & Investors." VCBacked, June 10, 2026, https://www.vcbacked.co/company/circio. Accessed July 2, 2026.

APA

VCBacked. (2026). Circio — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/circio

Wikipedia (cite web)

{{cite web |title=Circio — Funding & Investors |url=https://www.vcbacked.co/company/circio |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 10, 2026.